Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on for readers like you. LEARN MORE
Assess HER2 Status in Solid Tumors to Inform Eligibility for Enhertu

Request Your Free eGuide Now:

"Assess HER2 Status in Solid Tumors to Inform Eligibility for Enhertu"

This core visual aid from AstraZeneca and Daiichi Sankyo describes the relevance and prevalence of HER2 positivity across metastatic solid tumors; provides detail on the nuances of ASCO-CAP scoring criteria guidelines, including sample requirements and staining interpretation; and outlines who, when, and how to test for HER2 positivity using IHC testing.

Historically, HER2 has been identified as a predictive biomarker only in select tumor types — most notably in breast cancer. However, HER2-positive status is a negative prognostic factor in multiple metastatic solid tumors, often associated with more aggressive disease and a poor prognosis. What if there were more options for patients with HER2-positive (IHC 3+) metastatic solid tumors?


HER2-positive actionability has recently expanded beyond breast and gastric cancers to include non-small cell lung, endometrial, ovarian, cervical, colorectal, pancreatic, biliary tract, and bladder cancers, among others. Performing HER2 IHC testing in metastatic solid tumors at diagnosis can further the understanding of a patient’s disease state and biomarker profile.

Offered Free by: Astrazeneca
See All Resources from: Astrazeneca

Recommended for Professionals Like You: